Ovarian Cancer Update: FDA Grants Peptide Vaccine Orphan Status

A substantial breakthrough has taken place in the area of cancer treatment studies for ovarian cancer. New research demonstrates great potential for the immunotherpay DPX-Survivac, used to treat women with ovarian cancer. In early studies, patients exhibited great immune response to the therapy, coupled with a low-dose cyclophosphamide. In turn, the FDA has bestowed an […]